GEN Exclusives

More »

GEN News Highlights

More »
Sep 6, 2007

FDA Advisory Committee Reaches Consensus to Approve Merck’s HIV Therapy

  • Merck & Co. reports that an FDA advisory panel unanimously recommended accelerated approval of its HIV drug. The company anticipates the agency to make a decision by mid-October.

    If approved, Isentress™ , in combination with other antiretroviral therapy will be administered to treatment-experienced patients with ongoing viral replication despite existing therapy.

    Isentress could become the first in a new class of antiretroviral agents called integrase inhibitors. While current drugs act on protease and reverse transcriptase enzymes, Isentress inhibits the integrase enzyme. It thus prevents the insertion of HIV DNA into human DNA, blocking the ability of the virus to replicate and infect new cells, Merck explains.

    Merck is also preparing regulatory filings in countries outside the U.S.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?